StockData
Retension Pharmaceuticals, Inc. logo

Retension Pharmaceuticals, Inc. (RTSN) stock

RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$13.89+2.48 (+21.74%)

Close on Nov 18, 2026Market cap $11.22MP/E –Yield –

Retension Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Retension Pharmaceuticals's cash was $9.19M at Sep 30, 2026. For fiscal 2025 it was $18.90M, up 130.9% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.90M+130.9%
FY2024Dec 31, 2024$8.19M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$9.19M–
Q4 FY2025Dec 31, 2025$18.90M–
Q3 FY2025Sep 30, 2025$19.42M–
Q4 FY2024Dec 31, 2024$8.19M–

More Retension Pharmaceuticals figures

See a number that looks wrong?